Idioma:

Intravenous iron and iron deficiency anemia in patients with gastrointestinal cancer: A systematic review

Nandakumar, Shankavi ; Singh, Navreet ; Tharani, Alliya Remtulla ; Pankiw, Maya ; Brezden-Masley, Christine Strnad, Pavel

PloS one, 2024-05, Vol.19 (5), p.e0302964-e0302964 [Periódico revisado por pares]

United States: Public Library of Science

Texto completo disponível

Citações Citado por

Enviar para

Título:
Intravenous iron and iron deficiency anemia in patients with gastrointestinal cancer: A systematic review
Autor: Nandakumar, Shankavi ; Singh, Navreet ; Tharani, Alliya Remtulla ; Pankiw, Maya ; Brezden-Masley, Christine
Strnad, Pavel
Assuntos: Administration, Intravenous ; Analysis ; Anemia ; Anemia, Iron-Deficiency - drug therapy ; Bias ; Biology and Life Sciences ; Cancer ; Cancer patients ; Cancer therapies ; Care and treatment ; Case reports ; Chemotherapy ; Clinical trials ; Complications ; Complications and side effects ; Data collection ; Deficiency diseases ; Erythrocytes ; Erythropoietin ; Ferric carboxymaltose ; Gastrointestinal Neoplasms - complications ; Gastrointestinal Neoplasms - drug therapy ; Hemoglobin ; Humans ; Iron ; Iron - administration & dosage ; Iron - therapeutic use ; Iron deficiency ; Iron deficiency anemia ; Medical prognosis ; Medical research ; Medicine and Health Sciences ; Medicine, Experimental ; Mortality ; Neoplasms ; Nutrient deficiency ; Oncology ; Patients ; Physical Sciences ; Postoperative ; Quality of life ; Software ; Standard of care ; Supplements ; Systematic review ; Transfusion
É parte de: PloS one, 2024-05, Vol.19 (5), p.e0302964-e0302964
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
Competing Interests: I have read the journal’s policy and the authors of this manuscript have the following competing interests: Dr. Christine Brezden-Masley has received research funding from Novartis Pharmaceuticals Canada Inc., Eli Lilly Canada Inc., and Pfizer Canada Inc.; a travel grant from Knight, and honoraria; and has been involved as a consultant for Agendia Inc., Astellas, AstraZeneca, Bristol–Myers Squibb, Eisai, Eli Lilly Canada Inc., Gilead, Knight, Merck Sharp and Dohme LLC, Mylan, Novartis Pharmaceuticals Canada Inc., Pfizer Canada Inc., Roche, Sanofi, Seagen, and Taiho Pharma Canada Inc..
Descrição: Iron deficiency anemia (IDA) is a prevalent hematological complication associated with gastrointestinal (GI) cancers due to an increased loss of iron and decreased iron absorption. The purpose of this systematic review is to evaluate the use of parenteral iron to treat IDA in patients with GI cancer. PubMed, Cochrane, EMBASE, CINHAL and Scopus were searched from January 1, 2010 to September 29, 2023 with no language restrictions. We excluded editorials, case reports, abstracts, conference papers, and poster presentations. Studies were included if they discussed IDA, GI neoplasms, use of iron supplementation (with or without erythropoietin-stimulating agents [ESAs]), defined anemia and had an adult patient population. We assessed the efficacy of parenteral iron in comparison to other iron supplementation methods when treating IDA in patients with GI cancer. The Cochrane Risk of Bias Tool 2 (RoB 2) and the Risk Of Bias In Non-randomized Studies of Interventions (ROBINS-I) assessment tools were used to assess the quality of the included studies. Moreover, the Cochrane Effective Practice and Organization data collection form was used to collect pertinent study information. Our search yielded 3,969 studies across all databases. Twenty-one studies were included (6 randomized control trials; 15 non-randomized studies). Of the 15 studies evaluating hemoglobin (Hb) response, seven studies found an increase in Hb levels when patients were treated with IV iron. The 14 studies evaluating red blood cell (RBC) transfusion rates found conflicting differences in RBC transfusion needs when treated with IV iron. Studies analyzing health related outcomes typically found an increase in quality of life and decreased post-operative complications. This review demonstrates improved outcomes of IDA in patients with GI cancer treated with IV iron instead of other iron supplementation methods. Timely diagnosis and appropriate IDA management can greatly improve quality of life in this patient population, especially if myelosuppressive chemotherapy is required.
Editor: United States: Public Library of Science
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Intravenous iron and iron deficiency anemia in patients with gastrointestinal cancer: A systematic review

Nandakumar, Shankavi ; Singh, Navreet ; Tharani, Alliya Remtulla ; Pankiw, Maya ; Brezden-Masley, Christine Strnad, Pavel

United States: Public Library of Science

Buscando em bases de dados remotas. Favor aguardar.